Cervical cancer vaccine development.
Cervical cancer is initiated by infection of cervical epithelium with human papillomavirus. Vaccines have been developed, incorporating papillomavirus viral capsids and alum based adjuvants. In extensive clinical trials these vaccines have been shown safe and effective in preventing infection with, and disease caused by, the papillomavirus genotypes they incorporate, in women not already infected. These vaccines have the potential to reduce the global burden of cervical cancer by up to 70%.
Frazer
Ian H
IH
The University of Queensland Diamantina Institute, Princess Alexandra Hospital, Woolloongabba, Qld 4102, Australia. di.director@uq.edu.au
D064420:Drug-Related Side Effects and Adverse Reactions; D000939:Epitopes / Q000276:immunology; D005260:Female; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D052162:Human papillomavirus 16 / Q000276:immunology / Q000472:pathogenicity; D052161:Human papillomavirus 18 / Q000276:immunology / Q000472:pathogenicity; D006801:Humans; D032541:Mass Vaccination; D030361:Papillomavirus Infections / Q000276:immunology / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D011230:Precancerous Conditions / Q000276:immunology / Q000517:prevention & control; D011247:Pregnancy; D015229:Sexually Transmitted Diseases, Viral / Q000276:immunology / Q000517:prevention & control*; D002583:Uterine Cervical Neoplasms / Q000276:immunology / Q000517:prevention & control*; D058425:Vaccines, Virus-Like Particle / Q000008:administration & dosage / Q000276:immunology; D002578:Uterine Cervical Dysplasia / Q000276:immunology / Q000517:prevention & control*
D000939:Epitopes; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines; D058425:Vaccines, Virus-Like Particle